Show simple item record

dc.contributor.authorErdem-Ozdamar, Sevim
dc.contributor.authorGiger, Urs
dc.contributor.authorGelisin, Ozlem
dc.contributor.authorSerdaroglu-Oflazer, Piraye
dc.contributor.authorOzturk, Oguz
dc.contributor.authorToptas-Hekimoglu, Bahar
dc.contributor.authorInal-Gultekin, Guldal
dc.contributor.authorYilmaz-Aydogan, Hülya
dc.contributor.authorParman, Yesim
dc.contributor.authorUstek, Duran
dc.contributor.authorDeymeer, Feza
dc.contributor.authorGormez, Zeliha
dc.contributor.authorDurmus, Hacer
dc.contributor.authorPence, Sadrettin
dc.contributor.authorERGUNER, Bekir
dc.contributor.authorDEMİRCİ, Huseyin
dc.contributor.authorSAGIROGLU, Mahmut S.
dc.contributor.authorBekircan-Kurt, Can Ebru
dc.contributor.authorTan, Ersin
dc.date.accessioned2021-03-05T14:38:17Z
dc.date.available2021-03-05T14:38:17Z
dc.date.issued2017
dc.identifier.citationInal-Gultekin G., Toptas-Hekimoglu B., Gormez Z., Gelisin O., Durmus H., ERGUNER B., DEMİRCİ H., SAGIROGLU M. S. , Parman Y., Deymeer F., et al., "Myophosphorylase (PYGM) mutations determined by next generation sequencing in a cohort from Turkey with McArdle disease", NEUROMUSCULAR DISORDERS, cilt.27, ss.997-1008, 2017
dc.identifier.issn0960-8966
dc.identifier.otherav_b828044d-fd15-4bcb-b7b9-2d65b5ccb752
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/122529
dc.identifier.urihttps://doi.org/10.1016/j.nmd.2017.06.004
dc.description.abstractThis study aimed to identify PYGM mutations in patients with McArdle disease from Turkey by next generation sequencing (NGS). Genomic DNA was extracted from the blood of the McArdle patients (n = 67) and unrelated healthy volunteers (n = 53). The PYGM gene was sequenced with NGS and the observed mutations were validated by direct Sanger sequencing. A diagnostic algorithm was developed for patients with suspected McArdle disease. A total of 16 deleterious PYGM mutations were identified, of which 5 were novel, including 1 splice-site donor, 1 frame-shift, and 3 non-synonymous variants. The p.Met1Val (27-patients/11-families) was the most common PYGM mutation, followed by p.Arg576* (6/4), c.1827+7A>G (5/4), c.772+2_3delTG (5/3), p.Phe710del (4/2), p.Lys754Asnfs (2/1), and p.Arg50* (1/1). A molecular diagnostic flowchart is proposed for the McArdle patients in Turkey, covering the 6 most common PYGM mutations found in Turkey as well as the most common mutation in Europe. The diagnostic algorithm may alleviate the need for muscle biopsies in 77.6% of future patients. A prevalence of any of the mutations to a geographical region in Turkey was not identified. Furthermore, the NGS approach to sequence the entire PYGM gene was successful in detecting a common missense mutation and discovering novel mutations in this population study. (C) 2017 Elsevier B.V. All rights reserved.
dc.language.isoeng
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectNöroloji
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectNeurology
dc.subjectDevelopmental Neuroscience
dc.subjectCellular and Molecular Neuroscience
dc.subjectCognitive Neuroscience
dc.subjectGeneral Neuroscience
dc.subjectNeuroscience (miscellaneous)
dc.subjectSensory Systems
dc.subjectHuman-Computer Interaction
dc.subjectNeurology (clinical)
dc.subjectPhysical Sciences
dc.subjectLife Sciences
dc.subjectHealth Sciences
dc.subjectKLİNİK NEUROLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectNEUROSCIENCES
dc.subjectSinirbilim ve Davranış
dc.subjectYaşam Bilimleri (LIFE)
dc.titleMyophosphorylase (PYGM) mutations determined by next generation sequencing in a cohort from Turkey with McArdle disease
dc.typeMakale
dc.relation.journalNEUROMUSCULAR DISORDERS
dc.contributor.department, ,
dc.identifier.volume27
dc.identifier.issue11
dc.identifier.startpage997
dc.identifier.endpage1008
dc.contributor.firstauthorID97919


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record